Seaside Therapeutics Discontinues Arbaclofen (STX209) Extension Study

Source: 
The Boston Globe
Date Published: 
May 31, 2013
Abstract: 

Seaside Therapeutics has discontinued their extension study of Arbaclofen (STX209), a drug that showed promise in treating social impairment related to Fragile X syndrome.